BRAIN CYCLOSPORIN A LEVELS ARE DETERMINED BY ONTOGENIC REGULATION OF MDR1A EXPRESSION
Cyclosporin A (CyA) toxicity is a common occurrence in pediatric organ transplant patients. We hypothesized that reduced mdr1a expression in newborn and developing mice would affect CyA accumulation within organs and/or toxicity. For functional studies, CyA was administered (5 mg kg â1 i.p.) to 1-...
Saved in:
Published in | Drug metabolism and disposition Vol. 34; no. 2; pp. 288 - 295 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
Bethesda, MD
American Society for Pharmacology and Experimental Therapeutics
01.02.2006
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Cyclosporin A (CyA) toxicity is a common occurrence in pediatric organ transplant patients. We hypothesized that reduced mdr1a expression in newborn and developing mice would affect CyA accumulation within organs and/or toxicity. For functional studies,
CyA was administered (5 mg kg â1 i.p.) to 1-, 12-, and 19-day, and adult male and female mdr1a + / + and mdr1a â/â mice. Peak blood CyA was lower in 1-, 12-, and 19-day-old (1000 ng ml â1 ) versus adult (1500 ng ml â1 ) mice but was similar in mdr1a + / + and mdr1a â/â mice. Kidney mdr1a expression (measured by quantitative polymerase chain reaction) increased 2.5-fold in 19-day-old male and female mice and
increased another 4-fold in adult females compared with adult males. Liver mdr1a expression increased 6-fold by day 12 compared with neonatal mice. Thereafter, maintenance of hepatic mdr1a expression in females and a reduction to neonatal levels in males was observed. Kidney/blood (8- to 9-fold) and liver/blood
(12- to 15-fold) CyA levels were highest on days 12 and 19 and were not dependent on maturational changes in mdr1a mRNA levels. Adults had higher brain expression of mdr1a mRNA (3-fold), a corresponding 5-fold increase in immunodetectable P-glycoprotein, and 80% lower brain accumulation of CyA
compared with 1-day-old mice. Conversely, in mdr1a -null mice, brain/blood CyA was similar in newborn and adult mice. A similar pattern was observed for the brain accumulation
of the mdr1a substrate 3 H-digoxin. We conclude that the risk for central nervous system drug toxicity could be higher in neonates or young children
as a consequence of underdeveloped P-glycoprotein. |
---|---|
AbstractList | Cyclosporin A (CyA) toxicity is a common occurrence in pediatric organ transplant patients. We hypothesized that reduced mdr1a expression in newborn and developing mice would affect CyA accumulation within organs and/or toxicity. For functional studies,
CyA was administered (5 mg kg â1 i.p.) to 1-, 12-, and 19-day, and adult male and female mdr1a + / + and mdr1a â/â mice. Peak blood CyA was lower in 1-, 12-, and 19-day-old (1000 ng ml â1 ) versus adult (1500 ng ml â1 ) mice but was similar in mdr1a + / + and mdr1a â/â mice. Kidney mdr1a expression (measured by quantitative polymerase chain reaction) increased 2.5-fold in 19-day-old male and female mice and
increased another 4-fold in adult females compared with adult males. Liver mdr1a expression increased 6-fold by day 12 compared with neonatal mice. Thereafter, maintenance of hepatic mdr1a expression in females and a reduction to neonatal levels in males was observed. Kidney/blood (8- to 9-fold) and liver/blood
(12- to 15-fold) CyA levels were highest on days 12 and 19 and were not dependent on maturational changes in mdr1a mRNA levels. Adults had higher brain expression of mdr1a mRNA (3-fold), a corresponding 5-fold increase in immunodetectable P-glycoprotein, and 80% lower brain accumulation of CyA
compared with 1-day-old mice. Conversely, in mdr1a -null mice, brain/blood CyA was similar in newborn and adult mice. A similar pattern was observed for the brain accumulation
of the mdr1a substrate 3 H-digoxin. We conclude that the risk for central nervous system drug toxicity could be higher in neonates or young children
as a consequence of underdeveloped P-glycoprotein. Cyclosporin A (CyA) toxicity is a common occurrence in pediatric organ transplant patients. We hypothesized that reduced mdr1a expression in newborn and developing mice would affect CyA accumulation within organs and/or toxicity. For functional studies, CyA was administered (5 mg kg super(-1) i.p.) to 1-, 12-, and 19-day, and adult male and female mdr1a super(+) super(/) super(+) and mdr1a super(-/-) mice. Peak blood CyA was lower in 1-, 12-, and 19-day-old (1000 ng ml super(-1)) versus adult (1500 ng ml super(-1)) mice but was similar in mdr1a super(+) super(/) super(+) and mdr1a super(-/-) mice. Kidney mdr1a expression (measured by quantitative polymerase chain reaction) increased 2.5-fold in 19-day-old male and female mice and increased another 4-fold in adult females compared with adult males. Liver mdr1a expression increased 6-fold by day 12 compared with neonatal mice. Thereafter, maintenance of hepatic mdr1a expression in females and a reduction to neonatal levels in males was observed. Kidney/blood (8- to 9-fold) and liver/blood (12- to 15-fold) CyA levels were highest on days 12 and 19 and were not dependent on maturational changes in mdr1a mRNA levels. Adults had higher brain expression of mdr1a mRNA (3-fold), a corresponding 5-fold increase in immunodetectable P-glycoprotein, and 80% lower brain accumulation of CyA compared with 1-day-old mice. Conversely, in mdr1a-null mice, brain/blood CyA was similar in newborn and adult mice. A similar pattern was observed for the brain accumulation of the mdr1a substrate super(3)H-digoxin. We conclude that the risk for central nervous system drug toxicity could be higher in neonates or young children as a consequence of underdeveloped P-glycoprotein. Cyclosporin A (CyA) toxicity is a common occurrence in pediatric organ transplant patients. We hypothesized that reduced mdr1a expression in newborn and developing mice would affect CyA accumulation within organs and/or toxicity. For functional studies, CyA was administered (5 mg kg(-1) i.p.) to 1-, 12-, and 19-day, and adult male and female mdr1a+/+ and mdr1a-/- mice. Peak blood CyA was lower in 1-, 12-, and 19-day-old (1000 ng ml(-1)) versus adult (1500 ng ml(-1)) mice but was similar in mdr1a+/+ and mdr1a-/- mice. Kidney mdr1a expression (measured by quantitative polymerase chain reaction) increased 2.5-fold in 19-day-old male and female mice and increased another 4-fold in adult females compared with adult males. Liver mdr1a expression increased 6-fold by day 12 compared with neonatal mice. Thereafter, maintenance of hepatic mdr1a expression in females and a reduction to neonatal levels in males was observed. Kidney/blood (8- to 9-fold) and liver/blood (12- to 15-fold) CyA levels were highest on days 12 and 19 and were not dependent on maturational changes in mdr1a mRNA levels. Adults had higher brain expression of mdr1a mRNA (3-fold), a corresponding 5-fold increase in immunodetectable P-glycoprotein, and 80% lower brain accumulation of CyA compared with 1-day-old mice. Conversely, in mdr1a-null mice, brain/blood CyA was similar in newborn and adult mice. A similar pattern was observed for the brain accumulation of the mdr1a substrate 3H-digoxin. We conclude that the risk for central nervous system drug toxicity could be higher in neonates or young children as a consequence of underdeveloped P-glycoprotein. |
Author | David Worth Albert D. Fraser Christopher J. Sinal Kerry B. Goralski Philip D. Acott |
Author_xml | – sequence: 1 givenname: Kerry B surname: GORALSKI fullname: GORALSKI, Kerry B organization: Department of Pharmacology, Dalhousie University, Halifax, Nova Scotia, Canada – sequence: 2 givenname: Philip D surname: ACOTT fullname: ACOTT, Philip D organization: Department of Pharmacology, Dalhousie University, Halifax, Nova Scotia, Canada – sequence: 3 givenname: Albert D surname: FRASER fullname: FRASER, Albert D organization: Department of Pathology, Dalhousie University, Halifax, Nova Scotia, Canada – sequence: 4 givenname: David surname: WORTH fullname: WORTH, David organization: Toxicology Laboratory, Capital Health, Queen Elizabeth II Sciences Centre, Halifax, Nova Scotia, Canada – sequence: 5 givenname: Christopher J surname: SINAL fullname: SINAL, Christopher J organization: Department of Pharmacology, Dalhousie University, Halifax, Nova Scotia, Canada |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=17496409$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/16303871$$D View this record in MEDLINE/PubMed |
BookMark | eNpFkM9P2zAYhq2JCQrjuuPky3ZLsWM7P44hNV2kkKC0neBk2Y5NMyVNiakm_vsZtVJP76tPz_cenmtwsRt3BoDvGM0xDuldO7RzjNgcoZiG8RcwwyzEAULp8wWY-UBBylh0Ba6d-4sQppSkl-AKRwSRJMYzsLlvsqKC-Ute1qunuvE9gyX_w8sVzBoOF3zNm8ei4gt4_wLral0veVXksOHLTZmti7qC9QN8XDQ4g_z5qeGrlb99A1-t7J25PeUN2Dzwdf47KOtlkWdloElC3wOstLKxbSNpW6KSkFATKUYUTRS1ShrGFGYYRdrqVmncRrG2jLYmZIlMI0PIDfh13N1P49vBuHcxdE6bvpc7Mx6cwKm3QhLmwfkR1NPo3GSs2E_dIKcPgZH4FCm8SN-ZOIr0Dz9Oywc1mPaMn8x54OcJkE7L3k5ypzt35mKaRhSlZ27bvW7_dZMR-62cBqnHfnz9EISKUIRJQv4D5xKDXw |
CODEN | DMDSAI |
CitedBy_id | crossref_primary_10_1016_j_biomaterials_2009_09_048 crossref_primary_10_1021_tx300395w crossref_primary_10_1111_j_1440_1681_2010_05362_x crossref_primary_10_1016_j_neuro_2010_10_006 crossref_primary_10_1038_pr_2015_119 crossref_primary_10_1124_dmd_107_018556 crossref_primary_10_2967_jnumed_110_083949 crossref_primary_10_1016_j_taap_2013_12_019 crossref_primary_10_1021_jf104786t crossref_primary_10_1210_en_2009_0794 crossref_primary_10_1016_j_brainres_2010_08_016 crossref_primary_10_1016_j_ejps_2009_10_005 crossref_primary_10_1016_j_ejps_2019_105119 crossref_primary_10_1096_fj_202101552RR crossref_primary_10_1016_j_foodchem_2012_01_069 crossref_primary_10_1124_pr_109_002014 crossref_primary_10_3390_ijms18122544 crossref_primary_10_1002_jlcr_1604 crossref_primary_10_1016_j_brainres_2006_11_037 crossref_primary_10_1080_03602530802605040 crossref_primary_10_1002_bdd_752 crossref_primary_10_3389_fphar_2021_630904 crossref_primary_10_3389_fnins_2015_00021 crossref_primary_10_1097_FTD_0000000000000087 crossref_primary_10_15406_aowmc_2018_08_00234 crossref_primary_10_1074_jbc_M700793200 crossref_primary_10_1124_dmd_123_001517 crossref_primary_10_3389_fncel_2022_949412 crossref_primary_10_1124_dmd_107_018747 crossref_primary_10_1208_s12248_019_0340_z crossref_primary_10_1039_C6FO00938G |
Cites_doi | 10.1016/S0021-9258(19)52451-6 10.1016/0092-8674(94)90212-7 10.1002/aja.1002020209 10.1681/ASN.2004100882 10.1073/pnas.86.2.695 10.1016/j.transproceed.2004.01.051 10.1023/A:1010984110732 10.1146/annurev.bi.62.070193.002125 10.1016/j.transproceed.2003.12.053 10.1046/j.1440-169X.2003.00699.x 10.1172/JCI118214 10.1042/bj3260539 10.1023/B:PHAM.0000033017.52484.81 10.2310/6650.2001.33969 10.2165/00003088-200342020-00001 10.1097/00007890-200208270-00024 10.1007/s004670050607 10.1159/000047185 10.1016/j.transproceed.2004.01.013 10.1177/153537020523000206 10.1128/MCB.9.3.1346 10.1038/sj.jp.7210633 10.1046/j.1472-8206.2003.00140.x 10.1006/meth.2001.1262 10.1124/dmd.30.3.283 10.1002/(SICI)1097-4695(19990605)39:3<383::AID-NEU5>3.0.CO;2-4 10.1111/j.1476-5381.1996.tb15775.x 10.1124/dmd.105.003640 10.1007/s004670100602 10.1007/s004180050159 10.1007/s00467-003-1347-2 10.1016/S0009-9120(01)00235-1 10.1210/en.142.6.2686 10.1073/pnas.94.8.4028 10.1038/sj.bjp.0705227 |
ContentType | Journal Article |
Copyright | 2006 INIST-CNRS |
Copyright_xml | – notice: 2006 INIST-CNRS |
DBID | IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION 7TK |
DOI | 10.1124/dmd.105.007427 |
DatabaseName | Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef Neurosciences Abstracts |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Neurosciences Abstracts |
DatabaseTitleList | Neurosciences Abstracts MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1521-009X |
EndPage | 295 |
ExternalDocumentID | 10_1124_dmd_105_007427 16303871 17496409 34_2_288 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | - 08R 0R 2WC 4.4 53G 5GY 5RE 5VS AAPBV AAWZA ABFLS ABSGY ACGFS ACIWK ACPRK ADACO AENEX AFFNX AFRAH ALMA_UNASSIGNED_HOLDINGS CS3 DIK DU5 E3Z EBS EJD F5P FH7 FRP GJ GX1 H13 HZ IH2 INIJC KM KQ8 LSO O0- O9- OK1 P2P R0Z RHF RHI RPT SJN W2D WH7 WOQ --- .GJ 0R~ 18M ABSQV ACGFO ADBBV AFOSN AI. BAWUL BTFSW F9R HZ~ IQODW TR2 VH1 W8F YCJ YHG ZGI ZXP ~KM ABJNI AERNN CGR CUY CVF ECM EIF NPM AAYXX CITATION 7TK |
ID | FETCH-LOGICAL-c384t-1bcbf7fd6afd3b8234e6b53b48b4fbae55b15106cfcdbc1d67cf54de258a96e33 |
ISSN | 0090-9556 |
IngestDate | Fri Oct 25 07:09:14 EDT 2024 Fri Aug 23 02:56:16 EDT 2024 Sat Nov 02 12:31:03 EDT 2024 Sun Oct 22 16:03:39 EDT 2023 Tue Jan 05 21:17:02 EST 2021 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 2 |
Keywords | Ciclosporin Immunosuppressive agent Central nervous system Encephalon |
Language | English |
License | CC BY 4.0 |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c384t-1bcbf7fd6afd3b8234e6b53b48b4fbae55b15106cfcdbc1d67cf54de258a96e33 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
PMID | 16303871 |
PQID | 19742385 |
PQPubID | 23462 |
PageCount | 8 |
ParticipantIDs | proquest_miscellaneous_19742385 crossref_primary_10_1124_dmd_105_007427 pubmed_primary_16303871 pascalfrancis_primary_17496409 highwire_pharmacology_34_2_288 |
ProviderPackageCode | RHF RHI |
PublicationCentury | 2000 |
PublicationDate | 2006-02-01 |
PublicationDateYYYYMMDD | 2006-02-01 |
PublicationDate_xml | – month: 02 year: 2006 text: 2006-02-01 day: 01 |
PublicationDecade | 2000 |
PublicationPlace | Bethesda, MD |
PublicationPlace_xml | – name: Bethesda, MD – name: United States |
PublicationTitle | Drug metabolism and disposition |
PublicationTitleAlternate | Drug Metab Dispos |
PublicationYear | 2006 |
Publisher | American Society for Pharmacology and Experimental Therapeutics |
Publisher_xml | – name: American Society for Pharmacology and Experimental Therapeutics |
References | 2019091113251873000_34.2.288.22 (2019091113251873000_34.2.288.14) 1996; 270 (2019091113251873000_34.2.288.15) 2001; 61 (2019091113251873000_34.2.288.13) 1998; 2 (2019091113251873000_34.2.288.21) 2001; 49 (2019091113251873000_34.2.288.7) 2001; 18 2019091113251873000_34.2.288.8 2019091113251873000_34.2.288.9 (2019091113251873000_34.2.288.31) 1995; 275 2019091113251873000_34.2.288.19 2019091113251873000_34.2.288.1 2019091113251873000_34.2.288.17 (2019091113251873000_34.2.288.20) 1951; 193 2019091113251873000_34.2.288.39 2019091113251873000_34.2.288.16 (2019091113251873000_34.2.288.26) 1995; 202 2019091113251873000_34.2.288.38 2019091113251873000_34.2.288.3 2019091113251873000_34.2.288.37 2019091113251873000_34.2.288.4 2019091113251873000_34.2.288.36 2019091113251873000_34.2.288.5 2019091113251873000_34.2.288.35 2019091113251873000_34.2.288.12 2019091113251873000_34.2.288.34 2019091113251873000_34.2.288.11 2019091113251873000_34.2.288.33 2019091113251873000_34.2.288.10 2019091113251873000_34.2.288.32 2019091113251873000_34.2.288.30 (2019091113251873000_34.2.288.18) 2004; 21 (2019091113251873000_34.2.288.2) 2005; 230 2019091113251873000_34.2.288.29 2019091113251873000_34.2.288.28 (2019091113251873000_34.2.288.6) 1989; 9 2019091113251873000_34.2.288.27 2019091113251873000_34.2.288.25 2019091113251873000_34.2.288.24 2019091113251873000_34.2.288.23 |
References_xml | – volume: 193 start-page: 265 year: 1951 ident: 2019091113251873000_34.2.288.20 publication-title: J Biol Chem doi: 10.1016/S0021-9258(19)52451-6 – ident: 2019091113251873000_34.2.288.29 doi: 10.1016/0092-8674(94)90212-7 – volume: 202 start-page: 172 year: 1995 ident: 2019091113251873000_34.2.288.26 publication-title: Dev Dyn doi: 10.1002/aja.1002020209 – ident: 2019091113251873000_34.2.288.11 doi: 10.1681/ASN.2004100882 – ident: 2019091113251873000_34.2.288.5 doi: 10.1073/pnas.86.2.695 – volume: 275 start-page: 1011 year: 1995 ident: 2019091113251873000_34.2.288.31 publication-title: J Pharmacol Exp Ther – ident: 2019091113251873000_34.2.288.12 doi: 10.1016/j.transproceed.2004.01.051 – volume: 18 start-page: 957 year: 2001 ident: 2019091113251873000_34.2.288.7 publication-title: Pharm Res (NY) doi: 10.1023/A:1010984110732 – ident: 2019091113251873000_34.2.288.9 doi: 10.1146/annurev.bi.62.070193.002125 – volume: 61 start-page: 1469 year: 2001 ident: 2019091113251873000_34.2.288.15 publication-title: Cancer Res – ident: 2019091113251873000_34.2.288.24 doi: 10.1016/j.transproceed.2003.12.053 – ident: 2019091113251873000_34.2.288.27 doi: 10.1046/j.1440-169X.2003.00699.x – ident: 2019091113251873000_34.2.288.30 doi: 10.1172/JCI118214 – ident: 2019091113251873000_34.2.288.3 doi: 10.1042/bj3260539 – volume: 21 start-page: 1284 year: 2004 ident: 2019091113251873000_34.2.288.18 publication-title: Pharm Res (NY) doi: 10.1023/B:PHAM.0000033017.52484.81 – volume: 49 start-page: 250 year: 2001 ident: 2019091113251873000_34.2.288.21 publication-title: J Investig Med doi: 10.2310/6650.2001.33969 – ident: 2019091113251873000_34.2.288.33 doi: 10.2165/00003088-200342020-00001 – ident: 2019091113251873000_34.2.288.39 doi: 10.1097/00007890-200208270-00024 – ident: 2019091113251873000_34.2.288.1 doi: 10.1007/s004670050607 – ident: 2019091113251873000_34.2.288.36 doi: 10.1159/000047185 – ident: 2019091113251873000_34.2.288.16 doi: 10.1016/j.transproceed.2004.01.013 – volume: 230 start-page: 118 year: 2005 ident: 2019091113251873000_34.2.288.2 publication-title: Exp Biol Med (Maywood) doi: 10.1177/153537020523000206 – volume: 9 start-page: 1346 year: 1989 ident: 2019091113251873000_34.2.288.6 publication-title: Mol Cell Biol doi: 10.1128/MCB.9.3.1346 – ident: 2019091113251873000_34.2.288.38 doi: 10.1038/sj.jp.7210633 – ident: 2019091113251873000_34.2.288.34 doi: 10.1046/j.1472-8206.2003.00140.x – volume: 270 start-page: F756 year: 1996 ident: 2019091113251873000_34.2.288.14 publication-title: Am J Physiol – ident: 2019091113251873000_34.2.288.19 doi: 10.1006/meth.2001.1262 – ident: 2019091113251873000_34.2.288.10 doi: 10.1124/dmd.30.3.283 – ident: 2019091113251873000_34.2.288.22 doi: 10.1002/(SICI)1097-4695(19990605)39:3<383::AID-NEU5>3.0.CO;2-4 – ident: 2019091113251873000_34.2.288.23 doi: 10.1111/j.1476-5381.1996.tb15775.x – ident: 2019091113251873000_34.2.288.4 doi: 10.1124/dmd.105.003640 – volume: 2 start-page: 45 year: 1998 ident: 2019091113251873000_34.2.288.13 publication-title: Pediatr Transplant – ident: 2019091113251873000_34.2.288.25 doi: 10.1007/s004670100602 – ident: 2019091113251873000_34.2.288.32 doi: 10.1007/s004180050159 – ident: 2019091113251873000_34.2.288.35 doi: 10.1007/s00467-003-1347-2 – ident: 2019091113251873000_34.2.288.37 doi: 10.1016/S0009-9120(01)00235-1 – ident: 2019091113251873000_34.2.288.17 doi: 10.1210/en.142.6.2686 – ident: 2019091113251873000_34.2.288.28 doi: 10.1073/pnas.94.8.4028 – ident: 2019091113251873000_34.2.288.8 doi: 10.1038/sj.bjp.0705227 |
SSID | ssj0014439 |
Score | 2.0201318 |
Snippet | Cyclosporin A (CyA) toxicity is a common occurrence in pediatric organ transplant patients. We hypothesized that reduced mdr1a expression in newborn and... |
SourceID | proquest crossref pubmed pascalfrancis highwire |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 288 |
SubjectTerms | Age Factors Animals Animals, Newborn ATP Binding Cassette Transporter, Subfamily B - deficiency ATP Binding Cassette Transporter, Subfamily B - genetics ATP Binding Cassette Transporter, Subfamily B - metabolism ATP Binding Cassette Transporter, Subfamily B, Member 1 - metabolism ATP-Binding Cassette Sub-Family B Member 4 ATP-Binding Cassette Transporters - genetics ATP-Binding Cassette Transporters - metabolism Biological and medical sciences Brain - metabolism Cyclosporine - blood Cyclosporine - pharmacokinetics Female Gene Expression Regulation Immunosuppressive Agents - blood Immunosuppressive Agents - pharmacokinetics Kidney - metabolism Liver - metabolism Male Medical sciences Mice Mice, Knockout Pharmacology. Drug treatments RNA, Messenger - metabolism Sex Factors |
Title | BRAIN CYCLOSPORIN A LEVELS ARE DETERMINED BY ONTOGENIC REGULATION OF MDR1A EXPRESSION |
URI | http://dmd.aspetjournals.org/content/34/2/288.abstract https://www.ncbi.nlm.nih.gov/pubmed/16303871 https://search.proquest.com/docview/19742385 |
Volume | 34 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3LjtMwFLVg2LBBvCkMgxdoWHQCedh5LMtLIxBokFoxu8jP0UidtmrTRfn6uTd24lQwErCJorh1qpwT9177-FxCXltRloKbOLKJ1pCgGB1JJlWUGAPheWqMlLhR-Nv3_HTGvpzz8yAba3eXNPKt-vXHfSX_gypcA1xxl-w_INt3ChfgHPCFIyAMx7_C-D3WdxirnZovMTvFqYvxHFVAmzEKurSXurggE40KoKfWsvnCF-1qV9f1OhHo9O8UsYthuPpxvb3AItPAlHlXTUNf9kqvXryD2_x9AeyvZr3ehVrOE-UVIW7mJgiMIWLe-EraaLPVhJafnWox6O0H0xK9xMMPtVUcVdy5hndDrZ-3vBxkvH7cdLX9fh_PUwYg6CuN9YjR5pw5J4EBuKurFl2IK3ElPgn_a73asGu6Te6kaAeIS_c_wloTY5lLkvwP9taecOt3-zdGg1nf1X4U0zlLo7BWbODdsq4oys1ZSxu9TO-Tez7toBPHoQfkllk8JMdnzrd8d0KnYRve5oQe07PgaL57RGYt0eiAaHRCHdEoEI0GolG5oz3RaCAaXVraEo0Goj0ms8-fph9OI1-PI1JZyZookUrawupcWJ3JMs2YySXPJCsls1IYziXEj3GurNJSJTovlOVMm5SXospNlj0hB4vlwjwjNBaxTIsiT0yuWGyZiAW3KlOZtcpaXozIm-751itnu1K36WrKagAFznntQBmRo-7x16vBs6kzVqc18Ao-sAdK6K9gVc7iakRedSjVMLbigplYmOV2UycV6hhKPiJPHXjhu54Hz29seUHuhtfikBw06615CfFrI49a-l0DEzOeKg |
link.rule.ids | 315,783,787,27937,27938 |
linkProvider | Colorado Alliance of Research Libraries |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Brain+cyclosporin+A+levels+are+determined+by+ontogenic+regulation+of+mdr1a+expression&rft.jtitle=Drug+metabolism+and+disposition&rft.au=Goralski%2C+Kerry+B&rft.au=Acott%2C+Philip+D&rft.au=Fraser%2C+Albert+D&rft.au=Worth%2C+David&rft.date=2006-02-01&rft.issn=0090-9556&rft.volume=34&rft.issue=2&rft.spage=288&rft_id=info:doi/10.1124%2Fdmd.105.007427&rft_id=info%3Apmid%2F16303871&rft.externalDocID=16303871 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0090-9556&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0090-9556&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0090-9556&client=summon |